Systemic fungal infections in neonates

P C Ng

Fungal infection in newborn babies can present as mild, superficial mucocutaneous infection or as life threatening and disseminated sepsis. There are a number of ways in which fungal infection may be acquired. The infection may present at birth as congenital illness or later in life as nosocomial acquired infection.

(I) Acquired systemic fungal infections

Despite improvement in survival rates of very low birthweight (VLBW) infants, nosocomial infection remains an important contributing factor to neonatal morbidity and mortality. The emergence of fungi as important pathogens is likely to be the result of changes in the neonatal intensive care environment and their interaction with the host.

INCIDENCE

The incidence of disseminated fungal infection has not been systematically reported, due to problems in early recognition of the non-specific clinical symptoms and signs, and difficulty in confirming the diagnosis by laboratory tests. Current serological tests are not entirely reliable and microbiological cultures from sterile body fluids may only be intermittently positive, and even positive results may be misinterpreted as colonisation or contamination. A significant proportion of cases are only diagnosed at necropsy and those cases without postmortem examination would have been missed. Based on these limitations the incidence of acquired systemic fungal infections is estimated to be 2% to 5% among the VLBW infants, with species of candida being the most frequent invaders.

FACTORS PREDISPOsing TO SYSTEMIC FUNGAL INFECTION

Factors responsible for emergence of fungal infections in modern neonatal intensive care unit include impaired host defence, aggressive neonatal intensive care procedures, and prolonged use of broad spectrum antimicrobial treatment.

(a) Impaired host defence

The preterm infants' fragile skin and mucous membranes are very susceptible to contact injury which frequently results in the invasion of micro-organisms into deeper tissues. Specific immunological defence systems are also underdeveloped and transplacently acquired maternal IgG is low. T lymphocytes are reduced in number and are functionally incompetent with impaired cytokotic activity. Both phagocytic and bactericidal activities of polymorphonuclear leucocytes are sub-normal. The monocyte-macrophage system is immature with greatly suppressed chemotactic activity and inadequate nutrition undoubtedly further compromises immune status.

Immunocompetent term infants very rarely develop systemic fungal infections and they appear to have different risk factors from premature neonates. Most cases are associated with major congenital anomalies that include omphalocele, malrotation, sacrococcygeal teratoma, giant haemangioma, and congenital cyanotic heart disease. Infants who undergo complex surgery are also at a greater risk.

(b) Intensive care procedures

Invasive therapeutic and monitoring equipment has become an integral part of modern neonatal intensive care. Transcutaneous monitoring devices and adhesive tapes frequently cause superficial skin damage which facilitates the invasion of micro-organisms. Endotracheal tubes, urinary catheters, and indwelling vascular lines all bypass the skin barrier and enhance the susceptibility to systemic fungal infection by furnishing a portal of entry directly into the bloodstream. Although intravascular blood pressure monitoring devices and arterial cannulas may cause disseminated sepsis, the central venous line used for total parenteral nutrition is by far the most important apparatus responsible for fungal septicaemia. The administration of lipid emulsion may further increase the risk of fungaemia and narcotising pulmonary vasculitis due to lipophilic fungus. In addition, it has also been suggested that prolonged hospitalisation; prolonged stay in an incubator; extended period of endotracheal intubation; the use of tracheostomies; the requirement of an intraventricular shunt; and the use of lamb's wool, sticking plaster, and transparent semipermeable dressing may increase the risk of fungal colonisation and subsequent systemic infection. Equipment such as blood pressure cuffs, thermometers, oxygen saturation probes, and other diagnostic devices that are shared between infants may also promote the incidence of cross infection.
Systemic fungal infections in neonates

(c) Drugs
The suppression of the normal bacterial flora by prolonged and extensive use of broad spectrum antibiotics in VLBW infants has undoubtedly contributed to the increased incidence of fungal sepsis in sick premature infants.14 15 Theophylline has been reported to inhibit the candidicidal activity of human granulocytes.16 The liberal use of dexamethasone in bronchopulmonary dysplasia, however, is not associated with a significant increase in the incidence, or a change in the pattern, of infection.10 It seems that the anti-inflammatory potency of a particular steroid has little influence on its immunosuppressive action.

PATHOGENS
Candida and malassezia species are the two most frequent groups of opportunistic organisms causing disseminated fungal infection in premature neonates under 1500 g.5 6 Other opportunistic fungi such as aspergillus, cryptococcus, mucom, rhizopus, saccharomyces, Trichosporum beigeli, etc, are uncommon and usually occur sporadically. Pathogenic fungi which include coccidioides, paracoccidioides, and blastomycosis very rarely give rise to neonatal infections outside their endemic areas and are not a major problem in most neonatal units.

CANDIDA SPP
Candida albicans is the most frequent cause of fungaemia in premature VLBW infants. Other species of candida such as Candida parapsilosis, Candida tropicalis, Candida glabratre, and Candida lusitaniae have been reported to give a clinical picture indistinguishable from that caused by C albicans.

In most preterm infants, colonisation of candida occurs in utero or during delivery17 either by swallowing and aspirating the contaminated liquor, or by physical contact with the birth canal. Skin colonisation is common and often precedes the dissemination process.18 Infants with oropharyngeal and gastrointestinal tract colonisation may rarely have invasion of the bowel mucosa with resultant fungaemia.19 Candida pulmonitis secondary to aspiration is also uncommon.11 In contrast, babies colonised with candida after 2 weeks of age usually acquired the fungus nosocomially from caretakers.17

(a) Clinical presentation
The clinical features of systemic candidiasis in neonates are often non-specific and indistinguishable from bacterial sepsis. The onset is usually insidious and the mean age of infection is 33 days.1 The infant presents with temperature instability, carbohydrate intolerance, hypotension, apnoea, bradycardia, and deteriorating respiratory function which frequently requires ventilatory support. Feed intolerance, guaiac positive stools and generalised abdominal distension (without pneumatosi intesti-
nearly always significant, a negative culture does not exclude the diagnosis, as up to 20%-50% may not grow the organism. It must be emphasised that fungus grows more slowly than bacteria and antifungal treatment must therefore not be withheld in the absence of positive culture when clinical evidence is overwhelming. Examination of a Gram stained peripheral blood buffy coat preparation is sometimes useful for rapid diagnosis.

The presence of budding yeast and hyphae in a suprapubic urine sample is diagnostic of deep seated fungal infection. Culture from other sterile sites such as cerebrospinal fluid, ascites fluid, pleura, and tissue biopsy together with culture of indwelling catheters and long lines should be obtained when clinically indicated. Candida meningitis is difficult to diagnose. Despite an increase in the cerebrospinal fluid white cell count and protein concentration, microscopy is usually negative. Moreover, these parameters may also be increased with periventricular haemorrhage without fungal infection in the central nervous system. Surveillance cultures from ears, throat, umbilicus, and rectum may also be helpful in identifying the colonisation pattern of the individual patient.

Detection of candida antigens using various enzyme linked immunosorbent assay techniques appeared to be promising with a diagnostic sensitivity of about 70% when serial specimens are evaluated. However, serum levels of candida antigen can be raised in individuals who are heavily colonised or be undetectable in those with proved systemic candidiasis. The polymerase chain reaction technique, with its capability of detecting candida DNA fragments, may in future represent an important breakthrough for the early detection of candida sepsis. Measurement of candida metabolites such as D-arabinitol and biochemical tests such as the API-20c yeast test are of limited value and not routinely used in laboratories.

White cell and platelet counts are often abnormal in candida septicemia. Serial measurements of C reactive protein are particularly useful in monitoring the response to treatment. A chest radiograph may show pulmonary infiltrates and progressive air space consolidation but these changes are rather non-specific and not unique for candida pulmonitis.

Specific investigations are sometimes used to locate the focus of infection. Retinal examination may reveal fluffy white lesions on retina or vitreous, interlesional and lesional strands, and diffuse vitreous haze. Evidence of ventriculitis with foci of cavitary destruction and a network of fungal strands in the ventricles may be apparent on cranial ultrasound scan. Cardiac and renal ultrasound scans should be routinely performed. Intracardiac fungal infection may present as thrombi in the heart chambers and vegetations on the valves, whereas renal involvement may manifest as enlarged kidneys with highly echogenic parenchyma and fungal balls within the dilated pelvicalyceal systems. Percutaneous needle aspiration of the synovial cavity is indicated when neonatal fungal arthritis is suspected.

(d) Treatment

Three main categories of antifungal drugs are currently used for the treatment of systemic fungal infections. They are the polyene macrolide class compounds, the azoles, and inhibitors of RNA synthesis, the fluorinated pyrimidines.

Amphotericin B belongs to the polyene macrolide class of drugs and is the mainstay of treatment for opportunistic fungal infection. It must be administered intravenously for systemic effect as it is not absorbed enterally. The dosage could be increased in a stepwise fashion starting from 0.25 mg/kg/day up to a maximum of 1 mg/kg/day or administered as a constant dose of 0.6 mg/kg/day throughout the treatment period. The usual recommended duration of treatment is between three to six weeks. Combining amphotericin B treatment with flucytosine will permit the use of a lower dose and this combination is particularly effective for the treatment of central nervous system candida infection. Although the side effects are better tolerated by infants, fever, renal toxicity, gastrointestinal upset, bone marrow suppression, anaphylactic reaction, and severe electrolytes disturbances including hypokalaemia and hypomagnesaemia have been well documented. Electrolytes and renal and hepatic function must be monitored closely during the treatment period. Preparation of amphotericin B with parenteral lipid solution has been reported to reduce nephrotoxicity, improves clinical tolerance and permits a larger daily dose to be used.

A new formulation of amphotericin encapsulated in liposomes is commercially available. The resultant liposomal preparation is designed to maximise the delivery of amphotericin to deep seated sites of infection. The uptake by macrophages and the transport of liposomal amphotericin to the infective areas appear to play a major part in increasing efficacy and diminishing toxicity. Two reports indicate that liposomal amphotericin is effective in the treatment of disseminated fungal infections in VLBW infants. A starting dose of 1-5 mg/kg/day was used and this was increased progressively over a week to a maximum of 5 mg/kg/day. Side effects associated with conventional amphotericin such as fever, bronchospastic reactions, and renal toxicity were significantly less, but neonatal cholestasis with raised hepatic enzymes values and conjugated hyperbilirubinaemia has been observed. High dose liposomal amphotericin should be tried when the fungal infection is refractory or the baby is unable to tolerate conventional treatment.

The azole group of antifungals include the imidazoles such as miconazole, ketoconazole, and the newer triazoles such as fluconazole, itraconazole, and saperconazole. They are fungistatic agents. All triazoles show promise as broad spectrum, orally active, systemic antifungal drugs with less toxicity than the
Systemic fungal infections in neonates

Systemic fungal infections in neonates are associated with high morbidity and mortality in neonates with a significant proportion of cases being diagnosed at necropsy. Although central nervous system involvement usually has a poor prognosis and frequent neurological sequelae, intact survivors are occasionally seen. Current mortality rates range from 18% to 50%, but with a trend towards prompt and aggressive antifungal treatment, outcome should improve.

(1) Prevention

Since the colonisation of the newborn with subsequent mucocutaneous candidiasis may predispose to systemic candida infection, attempts have been made to eradicate the organism from the skin and gastrointestinal tract at risk infants. Clotrimazole vaginal tablets and cream given to pregnant women with vaginal candidiasis have significantly reduced the number of fungal contaminated newborns. Breast feeding has no impact on the incidence of oral thrush nor has chlorhexidine alcohol spray applied to the nipples of breast feeding women. The most promising prophylactic measure is perhaps the use of oral antifungal drugs, namely nystatin and micynazole oral gel, which has been shown to be effective in reducing the incidence of postnatally acquired gastrointestinal fungal colonisation. Nevertheless, the success of oral antifungal prophylaxis has not been translated into prevention of systemic candida infection in the newborns. As disseminated fungal infection is becoming more frequent among preterm neonates, there must be stringent control in the selection and usage of antibiotics, judicious use of indwelling lines and expedient weaning from mechanical ventilation. These must be combined with strict implementation of infection control surveillance measures in the intensive care nursery and especially careful handwashing.

MALASSEZIA SPP

Malassezia furfur is a lipophilic yeast. It is a frequent skin commensal and may colonise up to 64% to 84% of babies in a neonatal unit. Bronchopneumonia with necrotising pulmonary vasculitis and fungaemia in infants receiving parenteral lipid therapy have been reported. M furfur cannot be recovered from routine culture medium because it has an absolute nutritional requirement for medium chain fatty acids (C12-C24). Lipid enriched medium (such as Sabourand’s dextrose agar with olive oil and 0-2% Tween 80) is required for its culture. As most cases resolve quickly after parenteral lipid is stopped and indwelling venous catheter is removed, only a short course of amphotericin B is required. The prognosis is usually good if the diagnosis is made early and appropriate measures promptly implemented.

(e) Prognosis

Disseminated candida infections are associated with high mortality and mortality in neonates with a significant proportion of cases being diagnosed at necropsy. Although central nervous system involvement usually has a poor prognosis and frequent neurological sequelae,
infection is extremely rare but has been reported with candida, blastomycoses, coccidioides, and cryptococcus.

The syndrome of congenital systemic candida infection is very different from the more common acquired infection via haematogenous dissemination. Predisposing factors such as previous exposure to broad spectrum antibiotics, total parenteral nutrition, and central venous catheterisation are typically absent. The presence of a foreign body in the mother's genital tract such as an intrauterine contraceptive device or a cervical suture contributes to colonisation of Candida spp.5–24 Although severe candidal sepsis with pneumonia,23 septicemia, and meningitis3 have been reported, the pattern of organ involvement usually suggests a slow, locally invasive infection with little evidence of haematogenous dissemination, even in cases with deep tissue infection.33 Congenital candidiasis typically presents in the first week of life and may simulate congenital infection of bacterial origin or other conditions such as respiratory distress syndrome or idiopathic persistent pulmonary hypertension of the newborn. In most cases, candida can be recovered from surface swabs, endotracheal or gastric aspirates. Histological examination and culture of the placenta and umbilical cord may provide important evidence for the diagnosis.2 Blood and cerebrospinal fluid specimens, however, frequently fail to demonstrate the infection despite the presence of serious generalised candidiasis.33 Antifungal treatments are similar to postnatally acquired systemic candidiasis. Congenitally infected infants have a high mortality.33

Summary

Systemic fungal infections, previously considered to be a rare complication, are now frequently diagnosed in VLBW infants receiving intensive care. Confirming the diagnosis by laboratory tests is difficult and a high index of suspicion is required. Prompt and aggressive use of antifungal treatment is justified in a clinically septic neonate, especially those with a raised serum concentration of C reactive protein, who do not show a satisfactory response to antibiotics. The newer generation of liposomal amphotericin and azole antifungal drugs appear to be safe, effective, and well tolerated. With increasing awareness, prompt treatment, and better neonatal intensive care, the outcome of systemic fungal infection in preterm infants should improve.


Systemic fungal infections in neonates

P C Ng

*Arch Dis Child Fetal Neonatal Ed* 1994 71: F130-F135
doi: 10.1136/fn.71.2.F130

Updated information and services can be found at:
http://fn.bmj.com/content/71/2/F130.citation

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/